Introduction
Prostate cancer (PCa) is considered a neurotropic cancer, a commonality with other epithelial tumors such as pancreatic, bile duct, head/neck cancers [1] . PCa "neurogenesis" is an evolving field of research and considered a dominant pathway of local invasion [2] . Perineural invasion on prostate biopsy specimen may predict adverse outcomes after radical prostatectomy or radiation therapy; however, a consistent consensus has been hindered by variability in pathologic reporting and research study design [3] [4] [5] .
In vitro studies show the perineural space provides an enhanced environment for PCa survival and growth through cell-cell interactions involving growth factors [3, 6, 7] . Subsequent, animal models involving hypogastric denervation have prevented prostate cancer cell growth attributed to sympathetic and parasympathetic nerve alterations confirmed by increased nerve density in human PCa [8] . Moreover, a recent population based study showed β-blocker use may be associated with a reduction in PCa specific mortality suggesting that β-adrenergic receptor down-regulation may be the mechanism of action [9] .
Nerve Growth Factor (NGF) is overexpressed in the prostate and alterations in its receptors may cause PCa proliferation and metastasis. [10, 11] Herein, we investigate the potential utility of urinary NGF as a urinary biomarker for prostate cancer aggressiveness based on pathologic Gleason score.
Materials and Methods

Study Population and Design
After internal review board approval, we prospectively recruited patients at the pre-operative appointment prior to robotic assisted radical prostatectomy. Urine samples are collected when the participants had a strong desire to void. Subjects voided volume was added to the post void residual to calculate total bladder volume (TV) in order to control for volume concentration. The post-void residual volume was obtained by bladder scan ultrasound (Verathon BVI 3000 Bladderscan, Bothell, WA, USA) in all patients. In order to account for bladder volume and concentration the total urinary volume was calculated at the time of the void as well as a urinary creatinine, which has been used with NGF in previous studies [12] .
Sample Collection
Voided urine was placed on ice immediately and transferred to the laboratory for preparation for NGF measurement. The urine samples were centrifuged at 3000g for 10 min at 4°C. The supernatant was separated into aliquots in 1.5 mL tubes and preserved in a freezer at −80°C. At the same time, 3 mL of urine was taken to measure the urinary creatinine (Cr) level.
Urinary Nerve Growth Factor and Creatinine
Urinary NGF concentration was determined using an immunoassay system (Emax®, Promega, Madison, WI, USA) with a specific and highly sensitive ELISA kit, which had a minimum sensitivity of 7.8 pg/mL. Assays were conducted according to the manufacturer's instructions. The detailed procedure was described previously. Generally, urine samples were not diluted in the ELISA assay. When the urinary NGF concentration was higher than the upper detection limit (250 pg/mL) the urine samples were diluted to fit the detection limit. For urine samples with NGF concentrations lower than the detectable limit but above zero, they were concentrated using a column-protein concentrate kit (Amicon Ultra-15, Millipore, USA) before measuring the NGF value. All samples were run in triplicate, and urinary NGF levels without a consistent value in three measures were repeated and the values were averaged. The criterion for defining consistent values was that the coefficient of variation (SD/mean) of the three absorbance values was 0.10. If the coefficient of variation of the samples was 0.10, data of the first run were discarded and the samples were re-run in a triplicate. The concentration of urinary creatinine (mg/dL) assay kit (Cayman Chemical Company, Ann Arbor, MI, USA) was obtained and performed as per manufactures directions.
Study Outcomes
The primary outcome was NGF in patients with higher-grade prostate cancer compared to lower-grade prostate cancer found on final pathology after prostatectomy. Other preoperative, pathological and postoperative outcomes were also collected prospectively.
Pathological data consisted of pathologic Gleason as is grouped into three categories (Gleason 6 or less, Gleason 7, or Gleason 8 or greater). Tumor volume was determined as an overall percent of tumor in the radical prostatectomy specimen. If a range of percentages were given, the average percent tumor volume as calculated and used at the outcome. Additionally we documented positive surgical margins (PSM) and upstaging defined as any increase of Gleason pattern from biopsy to pathology (includes 3+4 to 4+3). The pathologist as per standard at our institution documented perineural invasion; however, no further quantification was performed. Final pathologic staging as per American Joint Committee on Cancer 2009 (AJCC) was used for analysis.
Postoperative oncologic follow-Up consisted of 3 month PSA and any PSA we could obtain thereafter for a goal of 12-month follow up. Biochemical recurrence was defined as a PSA >0.2 ng/mL with a confirmatory PSA or any patient who received adjuvant therapy.
Statistical Analysis
We performed the statistical analysis with SPSSv.21 statistical program (IBM). Urinary nerve growth factor (NGF) is not normally distributed; therefore, we transformed the variable with the log base 10 (Log NGF). Subsequently, we performed ANOVA and ChiSquared tests for associations of variables compared to pathologic Gleason score (three groups: Gleason 6 or less, Gleason 7, or Gleason 8 or greater). Other variables are tested with the Students T test or Chi-Square test. We then identified other independent variables associated with NGF, which could confound the association between pathologic grade and NGF using the Spearman correlations and ANOVA. Multivariate analysis using a general linear model for regression was performed including all variables found to be significantly associated with the dependent variable of interest log NGF. Only variables that were significant in the multivariate analysis were retained in the final model.
Results
After institutional review board approval, 120 consecutive men were recruited to participate in the study. Three men were excluded from analysis after enrollment due to having previous radiation therapy. The first subject had an undetectable NGF level though all other subjects had some level detected; therefore, this was attributed to error and the patient was excluded. One patient had a urinary tract infection and one patient was an outlier (NGF >1000 pg/mL) and is excluded from final analysis. Therefore, a total of 115 patients had all data available for analysis.
Previous studies noted an association of NGF with overactive bladder, anticholinergic medications, and prostatitis/chronic pelvic pain. [13, 14] We noted patients with moderate (AUAss >8, n= 48) and severe (AUAss >20, n=7) lower urinary tract symptoms (LUTS) had higher urinary LogNGF (1.34 pg/mL vs. Gleason score (p=0.018). Specifically, perineural invasion was noted to be more prevalent in higher-grade disease (p<0.001) (Figure 1a ).
Log NGF was significantly correlated with measurements of urine volume and concentration measured as total bladder volume (TV) (r=0.425, p<0.001) and urinary creatinine (r=0.451, p<0.001), respectively. Additionally PSA (r=0.284, p=0.002) and the presence of diabetes (p=0.012) were significantly associated with Log 10 NGF. (Table 2 ) There were no significant associations between Log 10 NGF and other pathologic factors such as perineural invasion (p=0.118), positive margin (p=0.397), prostate weight (0.080) or pathologic stage (p=0.761). (Table 2) Gleason group, urinary creatinine, total bladder volume, PSA, and diabetes were included as independent variables in a general linear model. (Table 2) 
Discussion
Among men presenting for robotic assisted radical prostatectomy, urinary nerve growth factor is higher in men with high-grade prostate cancer. We were not able to find significant differences in PSA or PSA density by Gleason grade in this cohort suggesting NGF may be a unique protein in prostate cancer aggressiveness. Previous studies have eluded that neurogenesis can be a mechanism of prostate cancer progression described alterations in nerve growth factor and its receptors. [8, 11] Our study is the first to explore this nerve growth factor as a potential urinary biomarker in prostate cancer.
Previous studies investigating neurogenesis in prostate cancer have stemmed from the common finding of perineural invasion in prostate cancer biopsy or prostatectomy specimens, including >75% of patients in our study [15, 16] . Unfortunately, the utility perineural invasion remains controversial. [4] Recent studies have invigorated the neurogenesis discussion by described changes in nerve density surrounding prostate cancer in radical prostatectomy specimens suggesting the cancer or surrounding tissue may be producing substances to induce nerve growth [8, 17, 18] . In vitro studies with prostate cancer cell lines have described relationships between PCa and nerve growth, specifically the interaction with secreted nerve growth factor [7, [19] [20] [21] .
NGF can stimulate low-grade PCa cell lines (LNCAP) to metastasize and high-grade cancer PCa cell lines (DU145 and PC3) can secrete NGF to recruit the nervous system similar to angiogenesis mechanisms [22] . Moreover, animal studies have shown that denervation of the hypogastric plexus of animals causes distinct morphologic and functional changes to the glandular epithelium independent of hormonal manipulation and can prevent prostate tumor development [8, 23] . If prostate cancer uses NGF to recruit nervous tissue as a component of progression, NGF pathway might be used as a biomarker or a therapeutic target.
A recent population based study of over 3,000 Norwegians suggested that β-blocker use is associated with reduced PCa specific mortality [9] . The β-blocker is postulated to inhibit cancer by reducing adrenergic stimulation thought to cause cancer progression and epithelial to mesenchymal phenotype switch [24, 25] . The concept of β-blocker use and potential modulation of neurogenesis to reduce progression have been shown across other tumors such as breast, ovarian and melanoma [26] [27] [28] . However, to our knowledge, urinary nerve growth factor has not been tested in a prospective observational clinical study for prostate cancer.
NGF has been found in prostatic fluid after prostate message, indicating that NGF is located in the prostate. [29] The previous studies were performed on prostatitis patients and we did confirm that NGF is elevated in men with inflammation on their prostatectomy specimens. We are unsure of the significance of this finding regarding prostate cancer, but there has been interest in prostatic inflammation and prostate cancer progression. [30] Another source of NGF could be the urothelium as described in patients with overactive bladder and bladder outlet obstruction. [12, 14] We documented the uroflometry, post void residual, and AUA symptom scores and noted that anticholinergic medication, elevated post void residual, and lower urinary tract symptoms were not associated with significant differences in LogNGF.
Although NGF has been detected in human prostate cancer tissue and studies supported that NGF may play a role in cancer invasion, there are very little studies about a possible role of NGF in the spread of prostate cancer. [10] Therefore, further studies are in progress to determine whether elevated urine NGF levels in patients with high-grade prostate cancer are associated with the expression of NGF in prostate cancer tissues or with circulating levels of NGF in prostate cancer patients due to cancer metastasis.
Limitations in this study stem from the pilot study design. We acknowledge the absence of control (non-cancer) patients from the study population. However, we were targeting the application in patients with a diagnosis of prostate cancer such as an active surveillance cohort. The origin of NGF is beyond the scope of this manuscript; however, other studies have shown the expression of NGF and its receptors in prostatic tissue. [29] Other organs and diseases that may also increase NGF that are not necessarily known and could change the results of the test. Moreover, we did not perform post-operative urine collection to confirm a reduction in NGF; however, it could be falsely elevated during the healing process. With limited resources, we chose to increase the sample size to assess the primary outcome of pathologic Gleason score. Due to these finding we are currently performing confirmatory testing of urinary NGF as a biomarker. Additionally, we collected urine at the preoperative appointment after prostate biopsy had occurred and acknowledge that the time from biopsy could change results of the test.
Future directions include incorporation of urinary biomarkers into clinical trials targeting neurogenesis, investigation of existing urine in biorepositories, and adjunctive testing in active surveillance cohorts.
Conclusions
In our pilot study, urinary nerve growth factor was able to distinguish high-grade prostate cancer prior to radical prostatectomy. Nerve growth factor may be a biomarker for highergrade prostate cancer and provide unique information for prostate cancer patients pending further confirmatory studies. 
